Cinflumide is an orally active muscle relaxant. Cinflumide shows antiinflammatory activity.

Choline hexanoate is an ionic liquid. Choline hexanoate exhibits cytotoxicity against breast cancer cells.

Chlorproguanil is an antifolate with an IC50 of 4.68 μM against Plasmodium falciparum female gamete formation.Chlorproguanil can be used for the research of malaria.

CHIKV-IN-1 (Compound 3a) is a compound that inhibits the Chikungunya virus (CHIKV) with an EC50 of 0.12 μM. CHIKV-IN-1 is a potent inhibitor of the S-adenosyl-L-homocysteine hydrolase (SAH hydrolase), with an IC50 of 0.36 μM. CHIKV-IN-1 is only effective against CHIKV and some other alphaviruses, but has no activity against other RNA viruses such as SARS-CoV, MERS-CoV, and ZIKV. CHIKV-IN-1 has extremely low cytotoxicity (CC₅₀ > 250 μM), and it has an extremely high selectivity index (SI > 2083). CHIKV-IN-1 can be used in research on anti-Chikungunya virus.

CHI3L1-IN-7 is a selective CHI3L1 inhibitor with a Kd of 7.40 μM and an IC50 of 15.4 μM. CHI3L1-IN-7 blocks CHI3L1's interaction with galectin-3, inhibits STAT3 phosphorylation, reduces the viability of multicellular 3D glioblastoma spheroids. CHI3L1-IN-7 can be used for the research of glioblastoma and CHI3L1-mediated tumor immune regulation.

CHI3L1-IN-6 (Compound 9e) is a CHI3L1 inhibitor with a Kd of 19.11 μM for hCHI3L1. CHI3L1-IN-6 blocks CHI3L1-Galectin-3 interaction. CHI3L1-IN-6 reduces STAT3 signaling. CHI3L1-IN-6 exhibits anti-cancer activity against glioblastoma.

CGS 27023A free base is a non-peptidic and orally active MMP inhibitor with the Ki values of 43, 33, 20 and 8 nM for MMP-3, MMP-1, MMP-2 amd MMP-9, respectively. CGS 27023A free base prevents cartilage degradation in stromelysin-induced rabbit cartilage degradation model. CGS 27023A free base can be used for study of arthritis.

CGP 29030A is an orally effective and specific analgesic agent. CGP 29030A inhibits nociceptive spinal cord neurons without affecting normal sensory functions. CGP 29030A also inhibits gamma motor neurons, which may be beneficial for studying pain disorders that occur concurrently due to increased motor activity (such as cramp, spasm).

Cefpodoxime (Cefpodoxime acid) sodium is a potent antibiotic active against gram-positive and gram-negative bacteria. Cefpodoxime inhibits the majority of cells in microbial populations. Cefpodoxime sodium can be used for acute otitis media, sinusitis and tosillopharyngitis research.

Ceftezole (GR69153) is a broad-spectrum cephalosporin antibiotic and an α-glucosidase inhibitor. Ceftezole inhibits bacterial cell lysis by inhibiting cell wall synthesis and binding to penicillin-binding proteins (PBPs). Ceftezole exhibits in vivo anti-diabetic activity in diabetic mice. Ceftezole can be used in antibacterial and anti-diabetic research.

CDK9-IN-49 is a CDK9 inhibitor with an IC50 of 7.32 nM. CDK9-IN-49 inhibits the proliferation of various cancer cells. CDK9-IN-49 can be used in the research of cancers such as acute myeloid leukemia and prostate cancer.

CDK9-IN-46 (Compound Formula I) is a CDK9 inhibitor. CDK9-IN-46 can be used for the research of cancer.

CDK2-IN-21 (example 30) is a potent cyclin-dependent kinase 2 (CDK2) inhibitor with an IC50 of 0.24 µM. CDK2-IN-21 can be used for cancer research.

CDC14A/B-IN-2, phosphotyrosine mimetic, is a competitive human CDC14A/B phosphatase inhibitor with IC50 values of 10.4 and 11.2 μM, and Ki values of 5.8 and 7.3 μM. CDC14A/B-IN-2 shows at least 20-fold selectivity over other protein tyrosine phosphatases. CDC14A/B-IN-2 can be used for the research of cancer.

CCR2 antagonist 6 (Example 98) is a CCR2 antagonist (Kb: 0.215 μM for CCR2, 0.174 μM for hCCR2B). CCR2 antagonist 6 can be used in the research of inflammation and autoimmune diseases.

CCL17-IN-2 (Compound Ex.128) is a CCL17 secretion inhibitor with an EC50 of 0.3 nM. CCL17-IN-1 can be used in the research of autoimmune diseases, dermatological conditions, and respiratory disorders.

CC-11 is an orally active small molecule drug conjugate (SMDC) that links the PI3K/mTOR inhibitor with the extracellular heat shock protein 90 (EHSP90) targeting ligand through a cleavable linker. CC-11 exhibits strong HSP90 binding activity (IC50 = 15 nM) and inhibits PI3Kα kinase activity (IC50 = 0.54 nM). CC-11 has anti-proliferative activity against colon cancer cells. CC-11 shows significant efficacy in the HCT-116 xenograft tumor model. CC-11 can be used for research on colon cancer.

CBP/p300/BRD4 ligand-1 is a small-molecule inhibitor targeting CBP, p300, and BRD4. CBP/p300/BRD4 ligand-1 competitively binds to the functional domains of target proteins without disrupting key interactions. CBP/p300/BRD4 ligand-1 can be used for the construction of dual-target PROTAC degraders in studies related to prostate cancer and other cancers.

CBP/p300 ligand-Linker Conjugate 3 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for CBP/p300 and a PROTAC linker, which recruits E3 ligases. CBP/p300 ligand-Linker Conjugate 3 can be used for synthesis of PROTAC CBP/P300 Degrader-2.

Cbl-b-IN-29 is an orally active CBL-B inhibitor. Cbl-b-IN-29 binds to the CBL-B active pocket. Cbl-b-IN-29 induces Jurkat cell release IL-2 with an EC50 of 159 nM, effectively inhibiting the function of immune E3 ubiquitin ligase. Cbl-b-IN-29 demonstrates robust anti-tumor efficacy in vivo with good tolerability and no observed adverse reactions. Cbl-b-IN-29 can be used for cancer immunotherapy, colorectal cancer and immune-oncology combination research.

Carboxyatractyloside (CATR) is a tight-binding inhibitor of adenine nucleotide translocase, and represents the major toxic component of Xanthium sibiricum. Carboxyatractyloside competes with ADP for binding to the translocase, blocks the translocation of ADP/ATP across the inner mitochondrial membrane, and thereby inhibits ADP-stimulated respiration. In the presence of Cyclosporin A, Carboxyatractyloside still induces permeability transition in liver mitochondria of aged rats, exhibiting significant hepatotoxicity and nephrotoxicity. Carboxyatractyloside is widely used in studies related to hepatotoxicity, nephrotoxicity and Alzheimer's disease.

Carbiphene is a GABAA receptor allosteric modulator. Carbiphene inhibits [35S] TBPS binding and enhances [3H] muscimol binding on rat forebrain membranes, acting on specific GABAA receptor subsets. Carbiphene can be used in research related to schizophrenia.

CaMKII-IN-3 (Example 321) is a CaMKII inhibitor with an IC50 of less than 10 nM. CaMKII-IN-3 can be used for the study of heart diseases.

CAD204520 dihydrochloride, a SERCA inhibitor (IC50 = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL). CAD204520 dihydrochloride can be used for T-ALL and MCL research.

CAB7-3 is an orally active HBV capsid assembly modulator (CAM). CAB7-3 exhibits an exceptional antiviral efficacy reducing HBV DNA with an EC50 = 70 nM, CC50 = 32.3 μM in HepDES19 cells. CAB7-3 exhibits significant anti-HBV activity in HBV-integrated HepDES19 (EC50 = 70 nM), HepAD38 (EC50 = 1 nM) and HBV-infected HLCZ01 cells (EC50 = 2 nM), respectively. CAB7-3 effectively reduces Hepatic HBV core protein levels and suppresses viral replication in vivo. CAB7-3 demonstrates a favorable drug-like and safety profile. CAB7-3 can be used for Hepatitis B Virus (HBV) research.

C14-Tri-LAN-Gly is a highly selective and potent NOD1 agonist. C14-Tri-LAN-Gly activates NOD1. C14-Tri-LAN-Gly inhibits the expression of cleaved-caspase3. C14-Tri-LAN-Gly upregulates A20 expression. C14-Tri-LAN-Gly protects mice from lethal hepatitis by inhibiting hepatocyte Apoptosis. C14-Tri-LAN-Gly inhibits osteoblastogenesis and promots osteoclastogenesis.

BRL 34778 is a potent, selective and orally active dopamine D2 receptor antagonist with a Ki of 2.14 nM. BRL 34778 exhibits antipsychotic activity with low activity for extrapyramidal effects and sedation. BRL 34778 can be used for the research of neurological disease, such as schizophrenia.

Brigimadlin (BI 907828) enantiomer is the Brigimadlin enantiomer. Brigimadlin is an MDM2 inhibitor with anti-cancer activity.

BRD3 ligand-1 is a target protein ligand that can be used for the synthesis of PROTACs, such as PROTAC BRD3 degrader-1.

BMS-442606, the S-enantiomer of 6-hydroxybuspirone (6OHB), is an orally active 5-HT1A partial agonist. BMS-442606 can be used for generalized anxiety disorder (GAD) research.